Don't let NEULAND get Out of Hand !!!

2023年7月18日

-Annual Revenue rose 26%, in the last year to Rs 1,200 Crores. Its sector's average revenue growth for the last fiscal year was 8.4%.
-Annual Net Profit rose 156.2% in the last year to Rs 163.5 Crores. Its sector's average net profit growth for the last fiscal year was 1.3%
-Price to Earning Ratio is 24.9, lower than its sector PE ratio of 42.6.
-FII/FPI have increased holdings from 18.14% to 20.19% in Jun 2023 qtr.
-Mutual Funds have increased holdings from 0.99% to 1.57% in Jun 2023 qtr.

Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.
Their products are exported to more than 35 countries including Germany, Italy, Switzerland, the UK and the Netherlands.

2023年7月27日

交易進行

2023年8月7日

註釋

Target 1 and counting - Approx 20% achieved so far

2023年8月10日

註釋

Target 2 Achieved

2023年8月17日

交易結束：目標達成

35% Achieved in about 4-5 Weeks